EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

PICCOS: study protocol for pressurised intraperitoneal aerosolised chemotherapy (PIPAC) in the management of cancers of the colon, ovary and stomach: a randomised controlled, phase II trial of efficacy in peritoneal metastases

Sadie E F Jones, Elena Brogden, Jamie Murphy, Christopher J Peters iD, Jonathan Frost, Richard Adams, Sarah Gwynne, Emma Hudson, Kitrick Perry, Angela Casbard, Rebecca Hamilton, Lisette Nixon und 18 weitere

Pleura and Peritoneum · 08.07.2026 · 11 (2) · 55-65

DOI: 10.1515/pp-2025-0023 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Pleura and Peritoneum, online erschienen am 01.05.2026. Verfasst von Sadie E F Jones und 29 weiteren Autor:innen. Beteiligte Einrichtung: Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, UK. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research - Efficacy and Mechanism Evaluation, MRC and NIHR, Welsh Government and Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Peritoneal metastases (PM) represent a significant unmet need requiring urgent development of treatment options to improve patient prognosis and quality of life (QoL). A novel anti-cancer technology is Pressurised IntraPeritoneal Aerosolised Chemotherapy (PIPAC). PIPAC aims to improve target specificity of anti-cancer therapies by delivering medication as an aerosol directly to the peritoneum at laparoscopy. Early phase I/II studies suggest that PIPAC has the potential to improve treatment efficacy and cancer outcomes whilst maintaining or improving QoL through less systemic drug absorption. PICCOS aims to determine whether PIPAC can improve peritoneal progression free survival (pPFS) in patients with PM from, compared to SACT alone.

Methods

PICCOS is a phase II, multi-centre, superiority, randomised controlled trial (ISRCTN 17575409). It aims to determine whether PIPAC (given alone or in combination with systemic anti-cancer therapy (SACT)) can improve peritoneal progression free survival (pPFS) as per RECIST (V1.1) in patients with PM, compared to SACT alone. Key secondary outcome measures include quality of life, safety, overall survival and progression free survival. 216 patients with non-resectable PM from colorectal cancer, platinum resistant ovarian cancer and gastric cancer will be recruited. Patients will be randomised to receive either standard of care SACT alone or PIPAC in combination with (colorectal, gastric groups) or without (ovarian group) standard of care SACT. Median pPFS will be estimated using the Kaplan–Meier method. The log-rank test, stratified by prognostic factors, will be used to compare PFS distributions.

Results

PIPAC is expected to achieve improved peritoneal progression free survival for patients in comparison to those treated with standard care.

Conclusions

PICCOS aims to provide much needed, high-quality evidence on the efficacy of PIPAC in treating PM.

Schlagwörter

Stichwörter der Autor:innen

PIPACperitoneal metastasesquality of liferandomised controlled trialresponse evaluation criteria in solid tumours (RECIST)

Autor:innen und Institutionen

  • Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, UK.
  • Centre for Trials Research, Cardiff University, Cardiff, UK.
  • Department of Surgery and Cancer, Imperial College London, London, UK.
  • Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
  • Swansea Bay University Health Board, Southwest Wales Cancer Centre, Swansea, UK.
  • Velindre University NHS Trust, Velindre Cancer Hospital, Cardiff, UK.

ORCID-Profile: Christopher J Peters, Peter Kyle

Förderung

  • National Institute for Health Research - Efficacy and Mechanism Evaluation
  • MRC and NIHR
  • Welsh Government and Cancer Research UK

Zitieren

APA

Jones, S. E. F., Brogden, E., Murphy, J., Peters, C. J., Frost, J., Adams, R., Gwynne, S., Hudson, E., Perry, K., Casbard, A., Hamilton, R., Nixon, L., Markham, P., Mohamed, H., Brown, G., Blazeby, J., Fitzsimmons, D., Ajakaiye, A., Batten, L. M., …, & Torkington, J. (2026). PICCOS: study protocol for pressurised intraperitoneal aerosolised chemotherapy (PIPAC) in the management of cancers of the colon, ovary and stomach: a randomised controlled, phase II trial of efficacy in peritoneal metastases. Pleura and Peritoneum, 11(2), 55-65. https://doi.org/10.1515/pp-2025-0023

Vancouver

Jones SEF, Brogden E, Murphy J, Peters CJ, Frost J, Adams R, et al. PICCOS: study protocol for pressurised intraperitoneal aerosolised chemotherapy (PIPAC) in the management of cancers of the colon, ovary and stomach: a randomised controlled, phase II trial of efficacy in peritoneal metastases. Pleura and Peritoneum. 2026;11(2):55-65. doi:10.1515/pp-2025-0023

BibTeX
@article{Jones2026,
  author = {Jones, Sadie E F and Brogden, Elena and Murphy, Jamie and Peters, Christopher J and Frost, Jonathan and Adams, Richard and Gwynne, Sarah and Hudson, Emma and Perry, Kitrick and Casbard, Angela and Hamilton, Rebecca and Nixon, Lisette and Markham, Philip and Mohamed, Huda and Brown, Gina and Blazeby, Jane and Fitzsimmons, Deborah and Ajakaiye, Anuoluwa and Batten, Leona M and Edgar, Maureen and Case, Amy and Kyle, Peter and Tate, Sophie and Arndell, Karen and Elliott, Daisy and Macefield, Rhiannon and Chuter, David and Hall, Harry and Garfitt, Joy and Torkington, Jared},
  title = {PICCOS: study protocol for pressurised intraperitoneal aerosolised chemotherapy (PIPAC) in the management of cancers of the colon, ovary and stomach: a randomised controlled, phase II trial of efficacy in peritoneal metastases},
  journal = {Pleura and Peritoneum},
  year = {2026},
  volume = {11},
  number = {2},
  pages = {55--65},
  doi = {10.1515/pp-2025-0023}
}
Kostenlos starten →